Yuhan Corporation

KOSE:A000100 Rapport sur les actions

Capitalisation boursière : ₩7.1t

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Yuhan Résultats passés

Passé contrôle des critères 5/6

Yuhan a connu une croissance annuelle moyenne de ses bénéfices de 4.3%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 10.1% par an. Les revenus ont augmenté de en hausse à un taux moyen de 5.2% par an. Le rendement des capitaux propres de Yuhan est 5.9% et ses marges nettes sont de 6.7%.

Informations clés

3.6%

Taux de croissance des bénéfices

2.9%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie11.3%
Taux de croissance des recettes5.3%
Rendement des fonds propres6.9%
Marge nette7.8%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26
Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Recent updates

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Jul 01
Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 13
Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26
Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

May 13
Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Mar 11
Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

May 01
Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Apr 16
Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Mar 15
Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Feb 25
Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Feb 10
Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

Jan 28
Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Jan 13
The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

Dec 31
Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

Dec 18
Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Dec 05
Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Nov 20
Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Ventilation des recettes et des dépenses

Comment Yuhan gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

KOSE:A000100 Recettes, dépenses et bénéfices (KRW Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 241,893,119147,849385,446146,919
31 Mar 241,860,529124,466378,998130,975
31 Dec 231,858,984133,993370,027119,920
30 Sep 231,872,33688,109365,050117,355
30 Jun 231,820,81176,045350,511114,124
31 Mar 231,808,041101,446355,579111,826
31 Dec 221,775,84795,144356,575107,103
30 Sep 221,749,31574,669359,069116,405
30 Jun 221,769,24597,836362,073112,866
31 Mar 221,719,63097,911355,095108,107
31 Dec 211,687,810102,583346,977106,677
30 Sep 211,725,26198,128350,567121,027
30 Jun 211,703,47597,833333,638128,767
31 Mar 211,685,62397,578321,279141,056
31 Dec 201,619,865192,761309,459142,634
30 Sep 201,552,188184,730292,514124,020
30 Jun 201,504,765168,667292,671109,357
31 Mar 201,448,677140,227291,60396,264
31 Dec 191,480,35440,006298,24996,900
30 Sep 191,500,78244,230295,95884,846
30 Jun 191,497,13041,438289,46086,652
31 Mar 191,523,95452,333285,11381,152
31 Dec 181,518,82357,481272,19974,067
30 Sep 181,481,90670,146260,11278,217
30 Jun 181,482,03484,572255,01172,563
31 Mar 181,450,870100,288254,54570,132
31 Dec 171,462,248109,034251,73371,435
30 Sep 171,434,749139,325247,12863,536
30 Jun 171,417,835137,434242,25360,608
31 Mar 171,395,518139,440233,21057,434
31 Dec 161,320,797161,249228,04852,667
30 Sep 161,274,011134,997229,65550,435
30 Jun 161,223,925155,819221,36848,078
31 Mar 161,163,130152,682209,37143,881
31 Dec 151,128,731126,047206,75639,016
30 Sep 151,097,229118,104199,13534,597
30 Jun 151,046,71698,362199,29730,754
31 Mar 151,031,87594,628202,27131,270
31 Dec 141,017,49290,948202,25930,915
30 Sep 141,007,10995,434200,30731,018
30 Jun 14970,25387,696192,80731,896
31 Mar 14953,19183,863193,99331,378
31 Dec 13943,60986,461192,51532,027
30 Sep 13879,99785,032188,92330,416

Des revenus de qualité: A000100 a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de A000100 (6.7%) sont supérieures à celles de l'année dernière (5.6%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de A000100 ont augmenté de 4.3% par an au cours des 5 dernières années.

Accélération de la croissance: La croissance des bénéfices de A000100 au cours de l'année écoulée ( 22.7% ) dépasse sa moyenne sur 5 ans ( 4.3% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices A000100 au cours de l'année écoulée ( 94.4% ) a dépassé celle du secteur Pharmaceuticals 22.7%.


Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de A000100 ( 5.9% ) est considéré comme faible.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé